CorePharmaDatasets Jirele
CorePharmaDatasets Jirele
CorePharmaDatasets Jirele
Datasets
Retail and Non‐Retail
Laura Jenkins Jirele
PMSA Virtual University
• PMSA Virtual University is conducting this 4 part webinar series focused on the
introduction and understanding of the current and evolving data resources
available in the Life Sciences industry.
• Beginning with this initial session which will build a foundation of understanding
for Life Sciences data, each subsequent session is designed to build on the prior
session to both expand and explore the evolving data available to the
Pharmaceutical industry.
– Session 1: Learn about core pharmaceutical datasets ‐ retail and non‐retail.
– Session 2: Dig deeper into analytics with APLD, EMR, and Specialty data.
– Session 3: The world of big data coming from the evolving digital world.
– Session 4: Understanding data behind the complex new world of health care involving IDNs and
ACOs.
• With a solid foundation of the data resources, PVU’ goal is to establish a venue for
discussion & collaboration on best practices in analytics, marketing and sales
operations.
• Industry Overview
• Past, Present & Future
• The Healthcare Information Flow
• Data Building and Sourcing
Agenda
• Retail Data
• Point of Service
• Mail‐Order
• Non‐Retail/Channel Data
• Managed Markets Data
• Summary/Q&A
3
Industry Overview
Past, Present & Future
The Pharma industry is in a constant state of change..
Portfolios and Leading Budgets and profits decline
Markets are shifting
Specialty &
Biologics
Generic
Erosion &
Non‐Retail
Blockbuster
Retail
Federal controls
grow stronger
Data resourcing is
Mergers and Acquisitions
exploding and imploding
in the US & globally
5 5
Syndicated data resources have greatly evolved over the past three decades
PBM
Expanded Social Sourcing GPO
use of Media
EMRs EHRs Sourcing
Complex Data
Integration
Big Data
Bio Similars ACOs
Data
ICD‐10s M&A
EMRs/ Registry
EHRs Data
Distribution
Data Medical What’s on the
Simple Data
Lab Data
Integration
Claims horizon?
Zip Level Physician Physician‐
Data Level Data Payor Level Patient
Data Level Data Digital Data
1980 1990
Late 2000 ‐ 2010 ‐
1990s …. 2016+
2010 2015
As the data evolved, more questions followed.
The evolution and dynamics shifts result in more complex questions which now
require different types of data sources and analytics to perform the even the basic
tasks and responsibilities in the home office and the field
7
Healthcare Information Flow
Where it Comes From
Common Terms
Branded Product Generic Products
Prescriptions (Rx):
(Branded) (Generic)
Federal Drug Enforcement
Healthcare Provider (HCP) Data Vendor
Agency (FDA):
National Council for Medical Care
Centers for Medicare &
Prescription Drug Organizations (Payer,
Medicaid Services (CMS)
Programs (NCPDP) MCO)
It starts all about the patient
The majority of pharmaceutical data comes from the billing and processing of
healthcare interactions for the care of a patient
10
From the perspective of a pharmaceutical company, the most important
information is the prescription and distribution of their product
WARNING: Pharma may only see what reaches
the pharmacy or mail‐order house!
11
When a patient sees a physician or goes to a clinic or hospital, a medical claim is
generated, which provides diagnosis and/or procedures, as well as many other
types of patient care information
Prescriber ID
• ID information
• License #
• Name
• Address
Patient Information
• Unique Anonymous Patient Identifier
• Name
• Address
• Gender
Treatment Information
• Date of Service
• Service Rendered (office visit, X‐Ray, etc)
• Illness or Diagnosis
• Charges
• Location of Service
• Provider of Service (MD, Lab, Ambul, etc)
• Plan of Treatment
• Duration of Treatments
12
An EMR/EHR database is a repository of all historical medical and prescription
activity, often providing a more granular and detailed account of a patient’s care
over time
Prescriber ID
• ID information
• License #
• Name/Address
Patient Information
• Unique Anonymous Patient Identifier
• Name/Gender
• Address
Treatment Information
• Date of Service
• Service Rendered (office visit, X‐Ray, etc)
• Illness or Diagnosis
• Charges
• Location of Service
• Provider of Service (MD, Lab, Ambulatory,
EMR: An electronic record within one health organization etc)
EHR: An electronic record that conforms to national standards • Plan of Treatment
and is used across organizations • Duration of Treatments
• Lab Data
• Test Results
• Physician Notes
13
Outside of the patient care spectrum, Pharma companies also have to manage a
complex balance of manufacturing, contracting and distribution
EDI data is the billing and tracking of drug/product information similar to the Rx/Medical
tracking of patient care.
850 180
Purchase Orders Returns Forms
• Placement of POs between • Product returns from wholesalers
wholesalers and manufacturers and client locations
• Return disposition codes
• Reason codes
EDI data can be used for analytics with marketing and sales with a solid 14
data strategy and integration infrastructure.
All of these information input streams are gathered and processed in varying
methods/volumes by vendors across the US
Writing
Submission Vendor
(Diagnosis, Processing
COLLECT Rx or QC (input Info) ADD (Payment MERGE Data SELL Data Build
Approval) Processing
Procedure)
Patient Name
Date
Prior info plus: Prior info plus: Prior info plus:
Physician Name Patient Name (if Patient Name Physician Specialty
Address not provided) (anonymized)
Designate’s Prescription Type (Nrx, Refill,
Telephone DEA # Plan Name
License Number Longitudinal Designation)
Rx: Insurance info Formulary Status Lists Concomitant Drug Usage
Product RX: Gender Hospital/Location of Care
Quantity to Pharmacy Age
Dispense Affiliations
Refills
Procedure/Test Agent (AMA, AOA, etc.)
DAW Location
Integration with other data sources
Dosage Referrals
Procedure /Test
Requirements
Jcode
ICD‐9
Note: Transmission & processing
ensures compliance with all HIPAA &
Govt Regulations
15
Once data is captured, cleansed and integrated, it is bucketed into broad
distribution channels
• Pharmacies
• Chain
• Independent • Specialty Mail
Retail • Mail‐order Specialty • Specialty distribution
• Food Stores networks
• Mass Merchandisers
• Hospitals
• HMOs • Marketing
Non‐ • Clinics Digital/ • Prescribing
• Social networks
Retail • LTC facilities
• Other Institutions Social • Websites
• Home Health Care • Virtual events
• Federal Hospitals • Unstructured data
• Direct purchasing (CDC) • New IT platforms
Gov’t • Prisons Big Data • Data Lakes, ponds
• Military (VA) • Real‐time integration
16
But these are evolving as well
Core Pharma Data Source
Retail & Non‐Retail Data
Retail data is typically a combination of Point‐of‐Sale data and Mail‐Order
volumes of NCPDP transactions
Retail Pharmacy
• Channel
• Pharmacy‐based
Mail‐ Order
• Standard Rx Data
• Standard Rx • Optional:
information Physician Linkage
• Physician linkage • Optional: Patient
• Payer Linkage
• Optional: Patient • Optional: Plan
information
18
NCPDP created a national standard for electronic healthcare transactions used in
prescribing, dispensing, monitoring, managing and paying for medications and
pharmacy services
• With hundreds of fields, this
data is both reliable, stable and
monitored
• This protocol, along with a daily
product distribution and overall
Rx volume provides a “stable”
ceiling for national projections
19
Examples of key retail data fields used by pharma for sales and marketing
analytics
20
Non‐Retail data provides an understanding of the distribution for where there is
no storefront, namely outlets, hospitals, etc.
• Non‐Retail
prescription
• Wholesaler
sales data
Sources
• Distributors
Types
• Channel (EDI)
data • Company’s
direct sales
• Hospital
operations • EDI invoices
data
21
Non‐Retail provides information on product movement through these wholesaler
or institutional channels such as hospitals, clinics, LTC facilities, etc.
• Once a product leaves the
manufacturer’s dock, Pharma often
loses track of “granular” sales
• Non‐retail data captures product
sales to end‐purchasers, giving our
clients the ability to gauge growth,
monitor “key” customer accounts
and evaluate their sales and
marketing efforts
22
What is a Wholesaler/Distributor?
They buy and sell products for a profit
• Purchase products in large quantities from
manufacturers at a 20% discount – “WAC”
• Re‐sell product to “end user” institutions such as:
pharmacies, hospitals, clinics, etc., for profit – “AWP”
They handle complex billing and distribution
activities
• Store products in warehouses strategically located
throughout the country to improve logistics
23
With the assembly of the invoice data and attributes, the sell‐in of products can
be tracked, and in some cases, the sell‐out as well
SOLD TO: SARTIN'S DISCOUNT DRUGS INC SUITE A PHONE: (985) 645-2500
4300 15TH STA DEA: AS2048557
GULFPORT, MS 39501 PHCY: 01681-01.1
AWP OR UNIT I
ITEM# QTY UM ITEM DESCRIPTION RETAIL PRICE GP% D CODE EXTENDED
PAGE 1
24
Key metrics used by Pharma companies with Non‐Retail data
25
Managed Markets data provides an understanding the payments, insurers and
reimbursement for retail and mail‐order products
• Formulary information
• Affiliation information
Sources
• Health Plans
• Prescribing behavior
Types
• Medical Claims
• Treatment behavior
• Prescription Claims
• Operating information
• Contracts/Transactions
• Pay Type & Payment
Information • Switch Networks
• Cost & patient pay
26
For Managed Markets data, all sourcing tracks back to health plans that provide
basic coverage, whether pharmacy or medical benefit
27
This complex tracking ensures that Managed Care (both Commercial and
Government) continues to have an increasing impact on Pharma
• Rebate, Contract
and Benefit dollars
pass through many
hands throughout
the Managed Dare
process
• New Government
mandates and
restrictions add
further
complexities
28
Impacts of Managed Care on Pharma have many moving parts and therefore
many dimensions
• Generally, pharmaceutical manufacturers have realized the
importance and advantages of being involved with Managed
Care, including:
– Rebates to plans for preferred placement on formularies
– Rebates to plans to limit restrictions even if preferred
– Rebates to pharmacies for stocking the product
– Direct involvement with both for discount and assistance
programs
– Advertising
– Restricted access to physicians through traditional means (office
visits, sampling)
– Mail‐Order/Home Delivery
– Patient Incomes (Wages)
– Patient Outcomes (Efficacy) It’s no longer maintenance of market share
– Generic erosion through physician targets or management of
– Government entitlements contracts, but additionally balancing patient
and payer dynamics as well
29
Pharma has long utilized both retail and non‐retail
resources for stable and reliable incentive compensation
plans
But that is quickly changing.
30
With the core sources, traditional pharma has managed
sales and marketing strategies
But knowledge, data and technology continue to
evolve, providing opportunities to enhance,
optimize and expand the insights to measure and
drive strategy.
31
Questions?